Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Italian Observational, Multicenter Study in HIV1 -Positive, Virosuppressed Patients Currently in Treatment With Ritonavir-boosted Protease Inhibitors (PI/r) Starting Cobicistat-boosted Darunavir (DRV/c - Rezolsta): the STart Of REzolsta (ST.O.RE.) Study

Next Previous
X
Search
Trial Profile

Italian Observational, Multicenter Study in HIV1 -Positive, Virosuppressed Patients Currently in Treatment With Ritonavir-boosted Protease Inhibitors (PI/r) Starting Cobicistat-boosted Darunavir (DRV/c - Rezolsta): the STart Of REzolsta (ST.O.RE.) Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cobicistat/darunavir (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms ST.O.RE.; STORE
  • Sponsors Janssen-Cilag

    • Most Recent Events

    • 08 Apr 2020 Results (n=348) published in The Patient - Patient-Centered Outcomes Research
    • 24 Feb 2020 Results (n=336) of final analysis were published in the JAIDS
    • 31 Oct 2018 Results presented at the 14th International Congress on Drug Therapy and HIV Infection

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top